Oncology CME

  • 30% OFF W/ CODE: SAVINGS30
    FEATURED

    The Brigham and Dana-Farber Board Review in Oncology

    This Oncology CME course will help you earn CME credits, MOC points, and prepare for medical Oncology board exams. 

    Topics covered in this course include:
    • Advances in Cancer Drug Development 
    • Symptom Management in Patients with Cancer
    • Infections in Cancer Patients
    • Breast Cancer: Risk Factors, Genetics, Screening and Prevention
    • Head and Neck Cancer
    • Prostate Cancer

    After completing this course physicians will be able to: 
    • Apply recommended oncology guidelines in clinical practice
    • Perform differential diagnosis of complex oncologic disorders
    • Identify and apply current therapeutic options for oncologic disorders
    • Evaluate and interpret up-to-date literature relevant to oncology
    • Apply knowledge gained to the ABIM certification/recertification oncology examinations

    Target Audience: Oncologists

     

    See full details chevron_right
    • Cost: $1295$907
    • Credit hours: 31,5
    • CME credits awarded by: Oakstone Publishing, LLC
    • Format: On-Demand Online, Online Video, Online Audio, Audio CD
    • Material last updated: June 30, 2018
    • Expiration of CME credit: June 30, 2021
  • FREE GIFT CARD

    Audio Digest Clinical Compendium: Oncology

    Free gift card with purchase!

    Own a collection of hand-selected lectures in the Oncology field. Clinical Compendium allows you unlimited access to 150 accredited lectures, presented by experts from the country’s leading medical institutions. Every lecture is accompanied by educational objectives, a written summary, and CME test questions.

    To make your access easy and efficient, we’ve grouped all these lectures into relevant clinical topics. Each topic is conveniently delivered in its own playlist to help you identify the content you are most interested in listening to at any time.

    CME credit is available for each lecture, with the potential to earn up to 119.25 AMA PRA Category 1 Credits™.

    See full details chevron_right
    • Cost: $1199
    • Credit hours: 119.25
    • CME credits awarded by: 3 years from date of publication
    • Format: On-Demand Online, Online Audio
    • Material last updated: Continuously updated
    • Expiration of CME credit: 3 years from date of publication
  • 30% OFF W/ CODE: SAVINGS30

    Practical Reviews in Cancer Management

    Practical Reviews in Cancer Management keeps you informed of the most important research and clinical findings published in Cancer Management each month.

    Each issue contains: downloadable audio of 12-15 articles summarized and reviewed in each issue; downloadable PDF of written reviews with Take-Home Pearls that reinforce the audio material and give you a valuable reference for instant recall by subject; and self-assessment online quizzes to highlight key points and reinforce what you’ve learned.

    Target Audience: Oncologists

    See full details chevron_right
    • Cost: $599$419
    • Credit hours: 56
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Format: On-Demand Online, Mobile App, Audio CD
    • Material last updated: Updated Monthly
    • Expiration of CME credit: Two years after date of publication
  • FEATURED

    The Audio Digest Oncology Board Review

    Get a free gift card with purchase as well as:

    • 55 lectures available on CDs and MP3s
    • Course content based on ABIM requirements
    • Appropriate for preparing for Certification or Recertification or as a comprehensive review of the specialty
    • Access to all lectures from your computer or the Audio Digest Mobile App
    • Earn 36 AMA PRA Category 1 Credits™
    See full details chevron_right
    • Cost: $1499
    • Credit hours: 36
    • CME credits awarded by: Accreditation Council for Continuing Medical Education (ACCME)
    • Format: On-Demand Online, Online Audio
    • Material last updated: Every 3 years
    • Expiration of CME credit: 3 years from date of publication
  • FEATURED

    BoardVitals Hematology and Oncology CME Board Review

    The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 CreditsTM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

    The BoardVitals Hematology and Oncology CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Hematology and Oncology test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

     

    Target Audience: Hematologists and Oncologists

    See full details chevron_right
    • Cost: $599
    • Credit hours: 27
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FREE

    Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly–Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

    Metastatic Melanoma: Novel Approaches discusses the epidemiology, causes, clinical features, pathogenesis and immunotherapy in the treatment of metastatic melanoma.

    By the end of Metastatic Melanoma: Novel Approaches, you will be able to:
    • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
    • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Describe emerging (investigational) therapies for metastatic melanoma
    • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

    Target Audience:
    Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 4, 2017
    • Expiration of CME credit: December 4, 2019
  • FREE

    Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy

    The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients.

    By the end of Oncology Patients at High Risk of Bone Fracture, you will be able to:
    • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
    • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
    Identify present pharmacotherapeutic treatments for management of a patient receiving • AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
    • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

    Target Audience:
    Oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 17, 2017
    • Expiration of CME credit: November 17, 2019
  • FREE

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics consists of a single presentation with discussion featuring Drs. Bradley J. Monk, MD and Robert L. Coleman, MD.

    At the conclusion of Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics, you will be able to:
    • Appraise the pathophysiology of ovarian cancer and their associated mutations, including germline and somatic BRCA mutations and other DNA repair deficiencies such as loss of heterozygosity
    • Evaluate the safety and efficacy data of PARP inhibitors
    • Use the latest diagnostic tools and genetic testing to identify patients who would benefit from PARP inhibitor therapy

    Target Audience:
    This program is intended for Medical and gynecologic oncologists, oncology nurses, nurse practitioners, pharmacists, and other health care professionals, including gynecologists, primary care physicians, physicians-in-training, and physician assistants involved in and/or interested in the management of patients with ovarian cancer.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Postgraduate Institute for Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: October 20, 2017
    • Expiration of CME credit: April 20, 2018
  • FREE

    Advances in Treating Metastatic Colorectal Cancer (CRC): Optimizing Recognition and Pharmacotherapeutic Management Strategies

    Advances in Treating Metastatic Colorectal Cancer (CRC) discusses the diagnosis and treatment of metastatic colorectal cancer (mCRC).

    By the end of Advances in Treating Metastatic Colorectal Cancer (CRC), you will be better able to:
    • Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
    • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
    • Describe the challenges and barriers to care associated with treating patients with mCRC

    In order to receive credit from ScientiaCME, you must first establish a username and password.

    Target Audience:
    Medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 19, 2017
    • Expiration of CME credit: October 19, 2019
  • FREE

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

    By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
    • Recall updates in the staging, prognosis, and diagnosis of MM.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

    Target Audience:
    Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 02, 2017
    • Expiration of CME credit: November 02, 2019